| BIOPHARMACEUTICAL-COMPANIES |
BIOPHARMACEUTICAL-COMPANIES |
92%
|
We believe biopharmaceutical companies are increasingly recognizing and appreciating the scientific and financial benefits of using our platform at scale. |
| CUSTOMER |
CUSTOMER |
92%
|
For the three months ended March 31, 2026, two customers accounted for 22 % and 18 % of total revenue, respectively. |
| CUSTOMERS-WITH-AN-ACV-OF-AT-LEAST-100-000 |
CUSTOMERS-WITH-AN-ACV-OF-AT-LEAST-100-000 |
92%
|
Our year-over-year customer retention rate for our customers with an ACV of at least $100,000 was 95% and was 92% or higher for each of the previous 10 fiscal years. |
| CUSTOMERS-WITH-AN-ACV-OF-AT-LEAST-500-000 |
CUSTOMERS-WITH-AN-ACV-OF-AT-LEAST-500-000 |
92%
|
Our customer retention rate for our customers with an ACV of at least $500,000 was 100%, 98%, 100% for the years ended December 31, 2024, 2023, and 2022, respectively. |
| SOFTWARE-CUSTOMERS |
SOFTWARE-CUSTOMERS |
92%
|
This is demonstrated by the length of our key relationships, with the average tenure of our 10 largest software customers in 2024 being nearly 21 years. |
| CDNS |
Cadence Design Systems, Inc. |
85%
|
Reciprocal relationship from CDNS graph: Reciprocal relationship from SDGR graph: g technology. Our ability to remain competitive will largely depend on our ability to continue to improve our computa… |
| CDNS |
Cadence Design Systems, Inc. |
85%
|
g technology. Our ability to remain competitive will largely depend on our ability to continue to improve our computational platform and demonstrate success in our drug discovery efforts. Our softwar… |
| SLP |
Simulations Plus, Inc. |
85%
|
Reciprocal relationship from SLP graph: Reciprocal relationship from SDGR graph: g technology. Our ability to remain competitive will largely depend on our ability to continue to improve our computat… |
| SLP |
Simulations Plus, Inc. |
85%
|
g technology. Our ability to remain competitive will largely depend on our ability to continue to improve our computational platform and demonstrate success in our drug discovery efforts. Our softwar… |
| APRE |
Aprea Therapeutics, Inc. |
72%
|
g technology. Our ability to remain competitive will largely depend on our ability to continue to improve our computational platform and demonstrate success in our drug discovery efforts. Our softwar… |
| APRE |
Aprea Therapeutics, Inc. |
72%
|
Reciprocal relationship from APRE graph: Reciprocal relationship from SDGR graph: g technology. Our ability to remain competitive will largely depend on our ability to continue to improve our computa… |
| BMY |
Bristol-Myers Squibb Company |
72%
|
respectively, and $ 350 and $ 3,939 of those milestones were recognized as revenue for the years ended December 31, 2023, and 2022, respectively. Drug discovery contribution revenue . Drug discovery … |
| BMY |
Bristol-Myers Squibb Company |
72%
|
Reciprocal relationship from BMY graph: Reciprocal relationship from SDGR graph: respectively, and $ 350 and $ 3,939 of those milestones were recognized as revenue for the years ended December 31, 20… |
| BMYMP |
Bristol-Myers Squibb Co |
72%
|
Reciprocal relationship from BMYMP graph: Reciprocal relationship from SDGR graph: respectively, and $ 350 and $ 3,939 of those milestones were recognized as revenue for the years ended December 31, … |
| BMYMP |
Bristol-Myers Squibb Co |
72%
|
respectively, and $ 350 and $ 3,939 of those milestones were recognized as revenue for the years ended December 31, 2023, and 2022, respectively. Drug discovery contribution revenue . Drug discovery … |
| GILD |
Gilead Sciences, Inc. |
72%
|
Reciprocal relationship from GILD graph: Reciprocal relationship from SDGR graph: Reciprocal relationship from GILD graph: Reciprocal relationship from SDGR graph: Reciprocal relationship from GILD g… |
| GILD |
Gilead Sciences, Inc. |
72%
|
research collaboration and license agreement with Novartis, we are responsible, together with Novartis, for the discovery of small molecule compounds directed against specified targets pursuant to mu… |
| GPCR |
Structure Therapeutics Inc. |
72%
|
Reciprocal relationship from GPCR graph: Reciprocal relationship from SDGR graph: Reciprocal relationship from GPCR graph: Reciprocal relationship from SDGR graph: performance-based vesting condition… |
| GPCR |
Structure Therapeutics Inc. |
72%
|
performance-based vesting conditions are considered probable as of that date. F-30 Table of Contents (11) . The Company has no obligation to fund Nimbus' losses in excess of its investment. gain or l… |
| LLY |
Eli Lilly and Company |
72%
|
Reciprocal relationship from LLY graph: Reciprocal relationship from SDGR graph: Reciprocal relationship from LLY graph: Reciprocal relationship from SDGR graph: Reciprocal relationship from LLY grap… |
| LLY |
Eli Lilly and Company |
72%
|
performance-based vesting conditions are considered probable as of that date. F-30 Table of Contents (11) . The Company has no obligation to fund Nimbus' losses in excess of its investment. gain or l… |
| MRK |
Merck & Co., Inc. |
72%
|
Reciprocal relationship from MRK graph: Reciprocal relationship from SDGR graph: Reciprocal relationship from MRK graph: Reciprocal relationship from SDGR graph: Reciprocal relationship from MRK grap… |
| MRK |
Merck & Co., Inc. |
72%
|
ontinuing voluntary cooperation in other areas. Individual European Union member states will continue to be responsible for assessing non-clinical (e.g., economic, social, ethical) aspects of health … |
| MYGN |
Myriad Genetics, Inc. |
72%
|
Reciprocal relationship from MYGN graph: Reciprocal relationship from SDGR graph: impact on our operations. Risks Related to Our Intellectual Property If we fail to comply with our obligations under … |
| MYGN |
Myriad Genetics, Inc. |
72%
|
impact on our operations. Risks Related to Our Intellectual Property If we fail to comply with our obligations under our existing license agreements with Columbia University, under any of our other i… |
| NVO |
Novo Nordisk A/S |
72%
|
Reciprocal relationship from NVO graph: Reciprocal relationship from SDGR graph: research collaboration and license agreement with Novartis, we are responsible, together with Novartis, for the discov… |
| NVO |
Novo Nordisk A/S |
72%
|
research collaboration and license agreement with Novartis, we are responsible, together with Novartis, for the discovery of small molecule compounds directed against specified targets pursuant to mu… |
| NVSEF |
Novartis AG |
72%
|
e software solution directly on their own in-house hardware and use it for a specified term, or (ii) a subscription that allows our customers to access our cloud-based software solution on their own … |
| NVSEF |
Novartis AG |
72%
|
Reciprocal relationship from NVSEF graph: Reciprocal relationship from SDGR graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from SDGR graph: e software solution directly on t… |
| RXRX |
Recursion Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from RXRX graph: Reciprocal relationship from SDGR graph: Reciprocal relationship from RXRX graph: Reciprocal relationship from SDGR graph: Reciprocal relationship from RXRX g… |
